By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – XDx today said that Highmark, a health insurer that covers around 4.8 million lives in Pennsylvania and West Virginia, is now covering its AlloMap test for beneficiaries of the health plan.

The AlloMap test is a gene expression-based assay used to aid the monitoring of heart transplant rejection. The test measures the expression levels of 20 genes from a blood sample to provide a score that is used by clinicians to help evaluate the risk of transplant rejection.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.